Werewolf Therapeutics (HOWL) News Today $1.33 -0.01 (-0.75%) As of 01/17/2025 04:00 PM Eastern Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 Time Period Werewolf Therapeutics, Inc. (NASDAQ:HOWL) Short Interest Up 13.2% in DecemberWerewolf Therapeutics, Inc. (NASDAQ:HOWL - Get Free Report) saw a significant growth in short interest in the month of December. As of December 31st, there was short interest totalling 1,720,000 shares, a growth of 13.2% from the December 15th total of 1,520,000 shares. Based on an average daily trading volume, of 773,000 shares, the days-to-cover ratio is currently 2.2 days. Currently, 5.2% of the company's shares are short sold.January 18 at 11:58 AM | marketbeat.comWerewolf Therapeutics price target lowered to $4 from $12 at JMP SecuritiesJanuary 14, 2025 | markets.businessinsider.comBank of America Securities Sticks to Its Buy Rating for Werewolf Therapeutics (HOWL)January 14, 2025 | markets.businessinsider.comWerewolf Therapeutics (NASDAQ:HOWL) Price Target Lowered to $4.00 at JMP SecuritiesJMP Securities cut their price objective on Werewolf Therapeutics from $12.00 to $4.00 and set a "market outperform" rating for the company in a research report on Tuesday.January 14, 2025 | marketbeat.comWerewolf Therapeutics provides business update, highlights 2025 outlookJanuary 14, 2025 | markets.businessinsider.comBuy Rating Affirmed for Werewolf Therapeutics Amid Strategic Advancements and Strong Financial PositionJanuary 14, 2025 | markets.businessinsider.comWerewolf Therapeutics, Inc.: Werewolf Therapeutics Provides Business Update and Highlights 2025 Strategic OutlookJanuary 13, 2025 | finanznachrichten.deWerewolf Therapeutics Provides Business Update and Highlights 2025 Strategic OutlookJanuary 13, 2025 | globenewswire.comBank of America Securities Sticks to Their Buy Rating for Werewolf Therapeutics (HOWL)January 7, 2025 | markets.businessinsider.comShort Interest in Werewolf Therapeutics, Inc. (NASDAQ:HOWL) Expands By 23.6%Werewolf Therapeutics, Inc. (NASDAQ:HOWL - Get Free Report) was the recipient of a significant increase in short interest in December. As of December 15th, there was short interest totalling 1,520,000 shares, an increase of 23.6% from the November 30th total of 1,230,000 shares. Based on an average daily trading volume, of 744,600 shares, the short-interest ratio is currently 2.0 days. Approximately 4.6% of the company's stock are sold short.December 31, 2024 | marketbeat.comShort Interest in Werewolf Therapeutics, Inc. (NASDAQ:HOWL) Declines By 6.1%Werewolf Therapeutics, Inc. (NASDAQ:HOWL - Get Free Report) saw a significant decline in short interest in November. As of November 30th, there was short interest totalling 1,230,000 shares, a decline of 6.1% from the November 15th total of 1,310,000 shares. Based on an average trading volume of 712,600 shares, the short-interest ratio is currently 1.7 days. Approximately 3.8% of the shares of the stock are short sold.December 17, 2024 | marketbeat.comWerewolf Therapeutics to Participate in the 7th Annual Evercore ISI HealthCONx Healthcare ConferenceNovember 20, 2024 | globenewswire.comInnovative Cytokine Immunotherapy: Werewolf Therapeutics’ Pioneering Approach and Promising PipelineNovember 19, 2024 | markets.businessinsider.comWerewolf Therapeutics' (HOWL) Buy Rating Reaffirmed at HC WainwrightHC Wainwright restated a "buy" rating and issued a $15.00 target price on shares of Werewolf Therapeutics in a report on Tuesday.November 19, 2024 | marketbeat.comFY2024 Earnings Estimate for HOWL Issued By Leerink PartnrsWerewolf Therapeutics, Inc. (NASDAQ:HOWL - Free Report) - Equities research analysts at Leerink Partnrs lifted their FY2024 earnings per share estimates for shares of Werewolf Therapeutics in a report issued on Monday, November 11th. Leerink Partnrs analyst D. Graybosch now forecasts that the comNovember 13, 2024 | marketbeat.comPromising Potential of Werewolf Therapeutics’ INDUKINE Platform Despite ChallengesNovember 13, 2024 | markets.businessinsider.comWerewolf Therapeutics Advances Innovative Cytokine TherapiesNovember 13, 2024 | markets.businessinsider.comBuy Rating for Werewolf Therapeutics: Strong Financial Position and Promising PipelineNovember 11, 2024 | markets.businessinsider.comWhat is HC Wainwright's Estimate for HOWL Q1 Earnings?Werewolf Therapeutics, Inc. (NASDAQ:HOWL - Free Report) - Equities research analysts at HC Wainwright issued their Q1 2025 earnings per share (EPS) estimates for Werewolf Therapeutics in a research report issued to clients and investors on Friday, November 8th. HC Wainwright analyst A. MaldonadoNovember 11, 2024 | marketbeat.comBuy Recommendation for Werewolf Therapeutics: Promising Developments in WTX-330 Clinical TrialsNovember 9, 2024 | markets.businessinsider.comWerewolf Therapeutics sees cash runway through 2Q26November 8, 2024 | markets.businessinsider.comWerewolf Therapeutics presents preclinical, clinical data on WTX-330November 8, 2024 | markets.businessinsider.comWerewolf Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business UpdateNovember 7, 2024 | markets.businessinsider.comWerewolf Therapeutics Presents Preclinical and Clinical Data at the Society for Immunotherapy of Cancer's (SITC) 39th Annual MeetingNovember 7, 2024 | globenewswire.comDark Wolf Nebula shows off a howling good view in awesome Halloween image (video)October 31, 2024 | msn.comLeonardo DiCaprio and Jane Goodall-Produced Movie ‘Howl’ Boarded by Pulsar Content, XYZ Films Ahead of AFM (EXCLUSIVE)October 31, 2024 | msn.comWerewolf Therapeutics announces addition of WTX-921 to pipelineOctober 31, 2024 | msn.comLeigh Whannell's Wolf Man Deviated From The Original Ryan Gosling Pitch, And The Writer/Director Told Me WhyOctober 22, 2024 | msn.comBank of America Predicts up to ~390% Surge for These 2 ‘Strong Buy’ StocksOctober 19, 2024 | msn.comWerewolf Therapeutics, Inc. (NASDAQ:HOWL) Short Interest UpdateWerewolf Therapeutics, Inc. (NASDAQ:HOWL - Get Free Report) saw a significant decline in short interest in September. As of September 30th, there was short interest totalling 1,040,000 shares, a decline of 7.1% from the September 15th total of 1,120,000 shares. Currently, 3.4% of the company's stock are short sold. Based on an average daily volume of 184,400 shares, the days-to-cover ratio is currently 5.6 days.October 16, 2024 | marketbeat.comMillennium Management LLC Raises Position in Werewolf Therapeutics, Inc. (NASDAQ:HOWL)Millennium Management LLC increased its stake in Werewolf Therapeutics, Inc. (NASDAQ:HOWL - Free Report) by 96.4% during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 1,110,298 shares of the company's stock after purchasing an adOctober 16, 2024 | marketbeat.comWerewolf Therapeutics to Present Posters at the Society for Immunotherapy of Cancer’s (SITC) 39th Annual MeetingOctober 5, 2024 | finance.yahoo.comWerewolf Therapeutics to Present Posters at the Society for Immunotherapy of Cancer's (SITC) 39th Annual MeetingOctober 4, 2024 | globenewswire.comRewilding eco-zealots have cried wolfSeptember 29, 2024 | yahoo.comRubric Capital Management LP Lowers Holdings in Werewolf Therapeutics, Inc. (NASDAQ:HOWL)Rubric Capital Management LP trimmed its stake in Werewolf Therapeutics, Inc. (NASDAQ:HOWL - Free Report) by 17.7% in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 1,333,893 shares of the company'sSeptember 21, 2024 | marketbeat.comWerewolf Therapeutics (NASDAQ:HOWL) Stock Price Down 3.6%Werewolf Therapeutics (NASDAQ:HOWL) Stock Price Down 3.6%September 13, 2024 | marketbeat.comWerewolf Therapeutics: A Buy Rating with Strong Upside Potential Amidst Market PullbacksSeptember 11, 2024 | markets.businessinsider.comWerewolf Therapeutics to Participate in the H.C. Wainwright 26th Annual Global Investment ConferenceSeptember 3, 2024 | markets.businessinsider.comAnalysts Offer Predictions for Werewolf Therapeutics, Inc.'s Q1 2025 Earnings (NASDAQ:HOWL)Werewolf Therapeutics, Inc. (NASDAQ:HOWL - Free Report) - Stock analysts at Leerink Partnrs issued their Q1 2025 earnings estimates for Werewolf Therapeutics in a research report issued to clients and investors on Monday, August 19th. Leerink Partnrs analyst D. Graybosch forecasts that the companAugust 22, 2024 | marketbeat.comAnalysts Offer Insights on Healthcare Companies: Werewolf Therapeutics (HOWL) and Chimerix (CMRX)August 21, 2024 | markets.businessinsider.comBrokers Issue Forecasts for Werewolf Therapeutics, Inc.'s Q3 2024 Earnings (NASDAQ:HOWL)Werewolf Therapeutics, Inc. (NASDAQ:HOWL - Free Report) - Equities research analysts at Leerink Partnrs issued their Q3 2024 earnings estimates for shares of Werewolf Therapeutics in a note issued to investors on Monday, August 19th. Leerink Partnrs analyst D. Graybosch expects that the company wAugust 20, 2024 | marketbeat.comBuy Rating Affirmed for Werewolf Therapeutics on Strong Candidate Progress and Promising Safety ProfilesAugust 10, 2024 | markets.businessinsider.comBuy Rating Affirmed: Werewolf Therapeutics’ Promising Pipeline and Financial HealthAugust 9, 2024 | markets.businessinsider.comHOWL Stock Earnings: Werewolf Therapeutics Misses EPS, Beats Revenue for Q2 2024August 8, 2024 | investorplace.comWerewolf Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business UpdateAugust 8, 2024 | globenewswire.com1,688,054 Shares in Werewolf Therapeutics, Inc. (NASDAQ:HOWL) Bought by Janus Henderson Group PLCJanus Henderson Group PLC acquired a new position in Werewolf Therapeutics, Inc. (NASDAQ:HOWL - Free Report) in the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund acquired 1,688,054 shares of the company's stock, valued atAugust 2, 2024 | marketbeat.comWerewolf Therapeutics, Inc. (NASDAQ:HOWL) Short Interest Up 55.1% in JulyWerewolf Therapeutics, Inc. (NASDAQ:HOWL - Get Free Report) was the recipient of a significant growth in short interest in July. As of July 15th, there was short interest totalling 1,050,000 shares, a growth of 55.1% from the June 30th total of 677,100 shares. Based on an average daily trading volume, of 313,000 shares, the short-interest ratio is presently 3.4 days. Currently, 3.5% of the shares of the company are sold short.July 27, 2024 | marketbeat.comWoman Captured Howling with Gigantic White Wolf in Beautiful FootageJuly 24, 2024 | msn.comWerewolf Therapeutics (NASDAQ:HOWL) Rating Reiterated by HC WainwrightHC Wainwright reissued a "buy" rating and set a $15.00 price objective on shares of Werewolf Therapeutics in a report on Tuesday.July 2, 2024 | marketbeat.comWerewolf Therapeutics (NASDAQ:HOWL) Given Market Outperform Rating at JMP SecuritiesJMP Securities restated a "market outperform" rating and set a $12.00 price target on shares of Werewolf Therapeutics in a report on Wednesday.June 26, 2024 | marketbeat.com Get Werewolf Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for HOWL and its competitors with MarketBeat's FREE daily newsletter. Email Address HOWL Media Mentions By Week HOWL Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. HOWL News Sentiment▼0.300.46▲Average Medical News Sentiment HOWL News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. HOWL Articles This Week▼72▲HOWL Articles Average Week Get Werewolf Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for HOWL and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies UroGen Pharma News Atai Life Sciences News Lifecore Biomedical News Heron Therapeutics News Design Therapeutics News Eledon Pharmaceuticals News COMPASS Pathways News Fulcrum Therapeutics News SOPHiA GENETICS News Larimar Therapeutics News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:HOWL) was last updated on 1/21/2025 by MarketBeat.com Staff From Our PartnersCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredStunning Trump Exec Order LeakedThis secret document contains stunning details about Donald Trump’s very first order of business… the minute h...Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode in 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredBuy this coin BEFORE Inauguration Day …Mark my words … Bitcoin is going to $100,000. BEFORE Trump is inaugurated. And I think it could reach $1...Weiss Ratings | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowThe crypto bull market is here, and the stakes couldn’t be higher. The next 3-6 months? They’re the most ex...Crypto Swap Profits | SponsoredMost People Are Dead Wrong.Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines ab...Brownstone Research | SponsoredElon’s New AI Firm REVEALEDNvidia’s AI chip … the H100 … has been the holy grail of artificial intelligence… Until now. Because Elo...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Werewolf Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Werewolf Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free HOWL Stock Alerts